We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prognostic and predictive values of CXCL10 in colorectal cancer.
- Authors
Chen, J.; Chen, Q.-L.; Wang, W.-H.; Chen, X.-L.; Hu, X.-Q.; Liang, Z.-Q.; Cao, Y.-b.; Cao, Y.-M.; Su, S.-B.
- Abstract
Background: The role of CXCL10 in progression and prognosis of colorectal cancer (CRC) has been studied for years, yet results remain controversial. Aim: This study aims to explore the relationship between CXCL10 and CRC progression and prognosis. Methods: We evaluated plasma CXCL10 in CRC patients using ELISA. We also performed a meta-analysis of the associations between CXCL10 and overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS), relapse-free survival (RFS), and clinicopathological features. Finally, correlations between CXCL10 and methylation or immune infiltration were performed using TCGA data. Results: ELISA analysis showed that CXCL10 was associated with age, red blood cells, blood platelets, and blood urea nitrogen. A separate analysis of 3,763 patients from 24 studies revealed that there were significant associations between low CXCL10 expression and OS (HR 1.25, 95% CI 1.01–1.53), DFS (HR 1.65, 95% CI 1.17–2.34), and RFS (HR 1.43, 95% CI 1.20–1.71) in CRC. Additionally, downregulated CXCL10 expression was significantly correlated with age [odds ratio (OR) 1.31, 95% CI 1.13–1.52], metastasis (OR 1.34, 95% CI 1.11–1.63), recurrence (OR 1.46, 95% CI 1.16–1.83), tumor location (OR 1.88, 95% CI 1.58–2.24), differentiation (OR 0.57, 95% CI 0.35–0.93), microsatellite instability (OR 0.23, 95% CI 0.15–0.35), BRAF mutation (OR 1.62, 95% CI 1.25–2.08), p53 mutation (OR 0.28, 95% CI 0.16–0.47), and CIMP (OR 0.27, 95% CI 0.17–0.43). Furthermore, significant associations were observed between CXCL10 and methylation and immune infiltration. Conclusions: The study suggests that CXCL10 might be a potential target for the treatment of CRC. Trial registration: NCT03189992. Registered 4 June 2017, https://www.clinicaltrials.gov/ct2/show/study/NCT03189992?term=NCT03189992&rank=1.
- Publication
Clinical & Translational Oncology, 2020, Vol 22, Issue 9, p1548
- ISSN
1699-048X
- Publication type
Article
- DOI
10.1007/s12094-020-02299-6